CBT
PPH icon

CoreFirst Bank & Trust’s VanEck Pharmaceutical ETF PPH Stock Holding History

CoreFirst Bank & Trust’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200
Closed -$18.1K – 335
2025
Q3 		$18.1K Hold
200
– – 0.01% 266
2025
Q2 		$17.6K Buy
+200
New +$17.3K 0.01% 270
2025
Q1 		– Sell
-200
Closed -$17.3K – 292
2024
Q4 		$17.3K Sell
200
-11,275
-98% -$1.02M 0.01% 272
2024
Q3 		$1.09M Buy
11,475
+1,215
+12% +$115K 0.63% 39
2024
Q2 		$939K Buy
10,260
+1,500
+17% +$134K 0.63% 40
2024
Q1 		$795K Buy
8,760
+10
+0.1% +$876 0.5% 47
2023
Q4 		$712K Buy
8,750
+7,800
+821% +$612K 0.47% 50
2023
Q3 		$75.9K Buy
+950
New +$76.6K 0.05% 193

Other funds holding PPH

Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CoreFirst Bank & Trust's PPH Position: Q4 2025 in Review

CoreFirst Bank & Trust sold out of VanEck Pharmaceutical ETF (PPH) in Q4 2025, closing a stake of 200 shares — an estimated $18.1K sold.

CoreFirst Bank & Trust first reported a position in PPH in Q3 2023 and held it in 8 quarters. The position peaked at $1.09M in Q3 2024. 146 funds tracked by Wall St. Rank hold PPH as of Q4 2025.

  • CoreFirst Bank & Trust reported no remaining VanEck Pharmaceutical ETF position as of Q4 2025 after selling out during the quarter.
  • CoreFirst Bank & Trust sold 200 VanEck Pharmaceutical ETF shares in Q4 2025, an estimated $18.1K.
  • CoreFirst Bank & Trust first reported a position in VanEck Pharmaceutical ETF in Q3 2023 and held it in 8 quarters.
  • CoreFirst Bank & Trust's VanEck Pharmaceutical ETF position peaked at $1.09M in Q3 2024.
  • 146 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q4 2025.

Based on CoreFirst Bank & Trust's 13F filing for Q4 2025, filed 11 Feb 2026.